|
Gene: NMB |
Gene summary for NMB |
Gene summary. |
Gene information | Species | Human | Gene symbol | NMB | Gene ID | 4828 |
Gene name | neuromedin B | |
Gene Alias | NMB | |
Cytomap | 15q25.2 | |
Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | P08949 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
4828 | NMB | LZE4T | Human | Esophagus | ESCC | 4.10e-49 | 2.19e+00 | 0.0811 |
4828 | NMB | LZE7T | Human | Esophagus | ESCC | 6.86e-07 | 6.66e-01 | 0.0667 |
4828 | NMB | LZE20T | Human | Esophagus | ESCC | 3.35e-09 | 4.98e-01 | 0.0662 |
4828 | NMB | LZE22T | Human | Esophagus | ESCC | 7.33e-10 | 8.66e-01 | 0.068 |
4828 | NMB | LZE24T | Human | Esophagus | ESCC | 2.62e-07 | 3.64e-01 | 0.0596 |
4828 | NMB | P1T-E | Human | Esophagus | ESCC | 7.84e-10 | 6.11e-01 | 0.0875 |
4828 | NMB | P2T-E | Human | Esophagus | ESCC | 1.68e-14 | 2.94e-01 | 0.1177 |
4828 | NMB | P4T-E | Human | Esophagus | ESCC | 5.38e-63 | 1.97e+00 | 0.1323 |
4828 | NMB | P5T-E | Human | Esophagus | ESCC | 2.54e-23 | 6.82e-01 | 0.1327 |
4828 | NMB | P8T-E | Human | Esophagus | ESCC | 2.92e-27 | 5.41e-01 | 0.0889 |
4828 | NMB | P9T-E | Human | Esophagus | ESCC | 5.15e-61 | 1.65e+00 | 0.1131 |
4828 | NMB | P10T-E | Human | Esophagus | ESCC | 6.29e-13 | 3.09e-01 | 0.116 |
4828 | NMB | P11T-E | Human | Esophagus | ESCC | 1.08e-12 | 9.97e-01 | 0.1426 |
4828 | NMB | P12T-E | Human | Esophagus | ESCC | 1.54e-13 | 3.44e-01 | 0.1122 |
4828 | NMB | P15T-E | Human | Esophagus | ESCC | 1.58e-38 | 1.18e+00 | 0.1149 |
4828 | NMB | P16T-E | Human | Esophagus | ESCC | 1.06e-29 | 5.77e-01 | 0.1153 |
4828 | NMB | P17T-E | Human | Esophagus | ESCC | 1.13e-05 | 2.24e-01 | 0.1278 |
4828 | NMB | P19T-E | Human | Esophagus | ESCC | 6.56e-09 | 1.86e+00 | 0.1662 |
4828 | NMB | P20T-E | Human | Esophagus | ESCC | 6.95e-13 | 4.38e-01 | 0.1124 |
4828 | NMB | P21T-E | Human | Esophagus | ESCC | 5.48e-62 | 1.79e+00 | 0.1617 |
Page: 1 2 3 4 5 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003195211 | Thyroid | ATC | regulation of protein autophosphorylation | 26/6293 | 43/18723 | 2.76e-04 | 1.77e-03 | 26 |
GO:200004522 | Thyroid | ATC | regulation of G1/S transition of mitotic cell cycle | 68/6293 | 142/18723 | 2.86e-04 | 1.82e-03 | 68 |
GO:005159225 | Thyroid | ATC | response to calcium ion | 69/6293 | 149/18723 | 8.43e-04 | 4.62e-03 | 69 |
GO:000716225 | Thyroid | ATC | negative regulation of cell adhesion | 127/6293 | 303/18723 | 1.45e-03 | 7.47e-03 | 127 |
GO:00487715 | Thyroid | ATC | tissue remodeling | 78/6293 | 175/18723 | 1.60e-03 | 8.04e-03 | 78 |
GO:003195411 | Thyroid | ATC | positive regulation of protein autophosphorylation | 17/6293 | 27/18723 | 1.70e-03 | 8.47e-03 | 17 |
GO:00457657 | Thyroid | ATC | regulation of angiogenesis | 141/6293 | 342/18723 | 1.80e-03 | 8.85e-03 | 141 |
GO:19013427 | Thyroid | ATC | regulation of vasculature development | 143/6293 | 348/18723 | 1.95e-03 | 9.44e-03 | 143 |
GO:003350024 | Thyroid | ATC | carbohydrate homeostasis | 109/6293 | 259/18723 | 2.56e-03 | 1.18e-02 | 109 |
GO:004259325 | Thyroid | ATC | glucose homeostasis | 108/6293 | 258/18723 | 3.27e-03 | 1.47e-02 | 108 |
GO:200013413 | Thyroid | ATC | negative regulation of G1/S transition of mitotic cell cycle | 40/6293 | 84/18723 | 5.33e-03 | 2.17e-02 | 40 |
GO:005105114 | Thyroid | ATC | negative regulation of transport | 183/6293 | 470/18723 | 8.12e-03 | 3.13e-02 | 183 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NMB | insertion | Frame_Shift_Ins | novel | c.230_231insAGCATATAGTGTGTGCATTTTGAAGGGA | p.Arg78AlafsTer19 | p.R78Afs*19 | P08949 | protein_coding | TCGA-A2-A0CP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
NMB | SNV | Missense_Mutation | c.365C>A | p.Pro122Gln | p.P122Q | P08949 | protein_coding | tolerated_low_confidence(0.25) | benign(0.005) | TCGA-G4-6309-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | xeloda | PD | |
NMB | SNV | Missense_Mutation | novel | c.384N>C | p.Gln128His | p.Q128H | P08949 | protein_coding | tolerated_low_confidence(0.21) | benign(0.138) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
NMB | SNV | Missense_Mutation | novel | c.418G>T | p.Val140Leu | p.V140L | P08949 | protein_coding | tolerated_low_confidence(0.59) | benign(0.001) | TCGA-AJ-A3BG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
NMB | SNV | Missense_Mutation | c.341N>A | p.Gly114Asp | p.G114D | P08949 | protein_coding | tolerated_low_confidence(0.12) | benign(0.058) | TCGA-BS-A0U7-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
NMB | SNV | Missense_Mutation | c.406N>A | p.His136Asn | p.H136N | P08949 | protein_coding | tolerated_low_confidence(0.05) | benign(0.015) | TCGA-D1-A0ZS-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
NMB | SNV | Missense_Mutation | c.388C>T | p.Arg130Cys | p.R130C | P08949 | protein_coding | tolerated_low_confidence(0.05) | benign(0.003) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
NMB | SNV | Missense_Mutation | novel | c.455G>A | p.Cys152Tyr | p.C152Y | P08949 | protein_coding | deleterious_low_confidence(0.02) | benign(0.01) | TCGA-22-1002-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
NMB | SNV | Missense_Mutation | novel | c.83G>A | p.Ser28Asn | p.S28N | P08949 | protein_coding | tolerated(0.13) | benign(0.006) | TCGA-CN-5373-01 | Oral cavity | head & neck squamous cell carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
NMB | SNV | Missense_Mutation | novel | c.289G>C | p.Ala97Pro | p.A97P | P08949 | protein_coding | deleterious(0.02) | possibly_damaging(0.735) | TCGA-CR-7364-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |